Trial Profile

A registrational Phase 3 study of sirexatamab plus bevacizumab and chemotherapy in second-line microsatellite stable Colorectal cancer (MSS CRC) patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 08 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antineoplastics (Primary) ; Bevacizumab (Primary) ; Sirexatamab (Primary)
Indications Colorectal cancer
Focus Registrational; Therapeutic Use

12 Nov 2025 According to Leap Therapeutics media release, the company expects to provide an update on the next steps in sirexatamab development and on the registrational pathway in the first quarter of 2026.
11 Feb 2025 New trial record
28 Jan 2025 According to Leap Therapeutics media release, positive signal from DeFianCe study supports Leap moving forward to plan a registrational Phase 3 clinical trial to evaluate sirexatamab plus bevacizumab and chemotherapy in second-line MSS CRC. Leap intends to conduct global commercial and regulatory strategic analysis to select the optimal population.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com